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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the effects of dual antibiotics for treatment of adults and children with non-cystic fibrosis bronchiectasis.
B A C K G R O U N D
Description of the condition
Non-cystic fibrosis bronchiectasis is a persistent respiratory condi-
tion associated with progressive destruction of the airways due to a
’vicious cycle’ of recurrent bacterial infection, pulmonary inflam-
mation and consequent structural damage (Cole 1997; Pasteur
2010). The pathological process of bronchiectasis leads to disrup-
tion of the normal epithelial barrier, which consequently allows
inhaled pathogens to both colonise the airways and cause clini-
cal episodes of infection (Cole 1986). In severe cases, this cycle
of infection may lead to repeated hospitalisation, chronic respi-
ratory failure and death. An understanding of the cycle is cen-
tral to the management of bronchiectasis, as strategies to arrest
both inflammatory and bacterial components are required to limit
progression of lung injury. Approximately half of presenting cases
are idiopathic, but the most common cause is a previous chest
infection, such as bacterial pneumonia or tuberculosis (Pasteur
2010). Diagnosis is based on identification of one or more abnor-
mally dilated bronchi on high-resolution computerised tomogra-
phy (HRCT) with characteristic symptoms including breathless-
ness, chronic productive cough and recurrent lower respiratory
tract infection (Chang 2010; Pasteur 2010). Patients colonised
with Pseudomonas aeruginosa and those with a frequent annual ex-
acerbation rate have an accelerated decline in lung function, re-
duced health-related quality of life (measured on St George’s Res-
piratory Questionnaire), increased risk of hospitalisation and in-
creasedmortality risk (Evans 1996;Martinez Garcia 2007;Wilson
1997). Low forced expiratory volume in one second (FEV1 )%pre-
dicted, a higher proportion of affected lobes and increased breath-
lessness are associated with increased risks of hospitalisation and
mortality (Chalmers 2014; Martinez Garcia 2014; Seitz 2010).
Bacteria most commonly associated with infective exacerbations
include non-typeable Haemophilus influenzae,Pseudomonas aerugi-
nosa, Streptococcus pneumoniae, Staphylococcus aureus andMoraxella
catarrhalis (Foweraker 2011). The microbiological profile differs
between adults and children, and Pseudomonas is more common
among adults. Pseudomonas is resistant to many oral antibiotics
and is very difficult to eradicate, but it is prevalent in only 0 to 6%
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of children. Colonising pathogens such as Pseudomonas, H influen-
zae and M catarrhalis also commonly display antimicrobial resis-
tance as the result of frequent exposure to antimicrobial agents.
The main aims of therapeutic management include preservation
of lung function; reduction in symptoms, such as cough, breath-
lessness and expectoration; reduction in the number and duration
of exacerbations; and improvement in quality of life (Lavery 2005;
Pasteur 2010).
Global prevalence estimates are confounded by variable diagnos-
tic strategies (Weycker 2005) and higher prevalence rates in de-
veloping countries (Habesoglu 2011), but the global burden of
bronchiectasis is increasing, with mortality rates rising by 3% per
year between 2001 and 2007 in England and Wales (Roberts
2010), and hospitalisations increasing by 3% per year over a nine-
year period in the United States (Seitz 2010). Both Roberts 2010
and Seitz 2012 reported higher prevalence rates among women
and in people over 60 years of age.More recent studies suggest that
prevalence may be increasing more rapidly than was previously
estimated. In Germany in 2013, prevalence was estimated at 67
cases per 100,000 general population (Ringshausen 2015). In the
UK, from 2004 to 2013, incidence rates rose by approximately
63%, with an increase from 21.2 to 35.2 in women and from 18.2
to 26.9 inmen, per 100,000 person-years (Quint 2016). Similarly,
point prevalence rose from 350.5 to 566.1 in women and from
301.2 to 485.5 in men, per 100,000 head of population, with ap-
proximately 262,900 adults in the UK living with bronchiectasis
in 2013. The disease has a significant impact on paediatric popu-
lations; younger children and those with more frequent exacerba-
tions experience worse quality of life (Kapur 2012a). Bronchiecta-
sis is more common in some ethnic groups, for example, southwest
Alaskan children (16:1000) and Australian aborigine children (15:
1000) (Chang 2002). Furthermore, one study reported an inci-
dence of 3.7 per 10000 per year among children younger than 15
years old in New Zealand. This equates to a prevalence of 1:3000
children overall and 1:625 in Pacific children () (Twiss 2005). It
also demonstrates that the incidence rate among children in New
Zealand is almost seven times higher than among those in Finland
(Twiss 2005). Average mortality rates per 100,000 general popu-
lation in Europe are estimated at 0.3 in 27 of the 28 EU countries
(ranging from 0.01 in Germany to 1.18 in the UK) and at 0.2
in nine non-EU countries (ranging from 0.01 in Azerbaijan to
0.67 in Kyrgyzstan), on the basis of 2005 to 2009 data (European
Lung White Book 2013). More recent UK figures estimate that
age-adjusted mortality rates are 2.26 times higher in women and
2.14 times higher in men compared with the general population
(Quint 2016).
Description of the intervention
The lungs of patients with non-cystic fibrosis bronchiectasis are
commonly colonised by bacteria, and treatment with antibiotics
can help to decrease bacterial load while reducing systemic in-
flammation (Kapur 2012). Antibiotics are used to reduce bacte-
rial burden and to tackle the cycle of infection and lung damage,
consequently helping to reduce the impact and frequency of chest
infection and the frequency and duration of hospital admissions
while also reducing mortality (Cole 1986; Pasteur 2010). Antibi-
otics can be administered on a short-term (< 4 weeks) or longer-
term (≥ 4 weeks) basis via various modes, including oral, inhaled
and intravenous routes, with specific choice of antibiotic informed
by analysis of sputum bacteriology. Antibiotics serve as front-line
therapy for management of bacterial load, but their use is weighed
against potential adverse effects and increasing concerns about an-
tibiotic resistance (Pasteur 2010).
’Combination’ or ’dual’ antibiotic therapy for non-cystic fibrosis
bronchiectasis is defined as the combination of two or more an-
tibiotics, rather than use of a single antibiotic (monotherapy), irre-
spective of the route of administration or the duration of therapy.
Dual antibiotic therapy is commonly administered therapeutically
over a short duration (up to four weeks), rather than prophylacti-
cally for prevention, and is commonly used to treat patients with
acute exacerbations whose lungs are colonised by multiple strains
of bacteria with different patterns of antibiotic resistance, when
monotherapy is unlikely to be effective. Dual therapy may also be
used when the clinician is concerned about increasing the risk of
antibiotic resistance, for example, when antibiotics have been pre-
scribed frequently or for a prolonged duration. British Thoracic
Society guidelines recommend the use of combination antibiotics
when patients present with multiple pathogens (Pasteur 2010).
How the intervention might work
Chronic bacterial airway colonisation commonly occurs in pa-
tients with non-cystic fibrosis bronchiectasis; high bacterial load
is associated with increased inflammation and symptoms and
worse quality of life (McShane 2013). It has been hypothesised
that inflammation contributes to progression of non-cystic fi-
brosis bronchiectasis, and evidence suggests that the presence of
bacteria in the airways promotes inflammation (Haworth 2014).
Bronchiectatic airways are commonly colonised by multiple bac-
teria or different strains of the same bacteria, some of which may
not be positively cultured in the laboratory. Bacterial load can
be reduced through treatment with systemic antibiotics (Rubin
2014), and various antibiotic strategies have been used to reduce
bacterial load and reinfection, including short-term (< 4 weeks)
therapy for acute exacerbations and longer-term (≥ 4 weeks)
prophylactic therapy for frequent exacerbations characterised by
chronic sputum purulence (Chalmers 2012; Evans 2003). Al-
though longer-term antibiotics are not recommended for routine
treatment (Valery 2012; Wu 2014), they may be considered for
treatment of patients with frequent exacerbations (three or more
per year requiring antibiotic therapy) (Pasteur 2010). Dual an-
tibiotic therapy for exacerbations could reduce bacterial load and
levels of inflammation, consequently improving clinically mean-
2Dual antibiotics for non-cystic fibrosis bronchiectasis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ingful outcomes, such as length of exacerbation, frequency of ex-
acerbation, disease progression and mortality.
Why it is important to do this review
The benefits and risks of dual antibiotics given for management
of acute exacerbations and for prophylaxis are currently unclear. It
is important to weigh the benefits of dual antibiotics in terms of
bacterial eradication and suppression of bacterial load against the
risks of enhanced antibiotic resistance and exposure to side effects
associated with multiple antibiotic therapy.
This review aims to summarise available evidence on the use of
dual antibiotics for patients with bronchiectasis to inform clinical
practice and future research needs. This review is being conducted
alongside two other, closely related reviews: Macrolide antibiotics
for non-cystic fibrosis bronchiectasis andHead-to-head trials of antibi-
otics for non-cystic fibrosis bronchiectasis.
O B J E C T I V E S
To evaluate the effects of dual antibiotics for treatment of adults
and children with non-cystic fibrosis bronchiectasis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs). We will in-
clude studies reported as full text, those published as abstract only
and unpublished data.
Types of participants
We will include adult and paediatric participants with a clinical
diagnosis of bronchiectasis confirmed by plain film chest radio-
graph or HRCT. We will exclude studies in which participants
were receiving continuous or high-dose antibiotics immediately
before the study began or had received a diagnosis of cystic fibrosis
(CF), sarcoidosis or active allergic bronchopulmonary aspergillo-
sis.
Types of interventions
The main aim of this review is to compare the effectiveness of
combined antibiotics versus monotherapy. As a secondary aim, we
will compare the effectiveness of one combination of antibiotics
versus another.We will include studies comparing dual antibiotics
versus a single antibiotic, provided that both arms include a com-
mon route of administration. . We will analyse short-course (< 4
weeks) and long-term (≥ 4 weeks) dual antibiotics separately. This
review will focus on comparisons of antimicrobial agents and will
exclude comparisons of macrolides owing to their anti-inflamma-
tory properties. Potential comparison groups for dual therapy ver-
sus monotherapy include the following.
1. Oral dual therapy versus oral monotherapy.
2. Intravenous dual therapy versus intravenous monotherapy.
3. Oral + inhaled dual therapy versus oral monotherapy.
4. Oral + intravenous dual therapy versus oral monotherapy.
5. Inhaled + intravenous dual therapy versus inhaled
monotherapy.
6. Inhaled + oral dual therapy versus inhaled monotherapy.
7. Intravenous + inhaled dual therapy versus intravenous
monotherapy.
8. Intravenous + oral dual therapy versus inhaled
monotherapy.
We will include studies comparing one combination of antibiotics
versus another if they compare different classes of antibiotics in
combination or different administration routes of agents from
the same class (e.g. IV cephalosporin + IV aminoglycoside vs IV
cephalosporin + inhaled aminoglycoside).
Types of outcome measures
Primary outcomes
1. Successful treatment of exacerbation
2. Length of exacerbation
3. Length of hospitalisation
4. Time to next exacerbation
5. Frequency of exacerbations
6. Serious adverse event
Secondary outcomes
1. Response rates as defined by study authors (e.g. diary cards
of physician global assessment)
2. Sputum volume and purulence
3. Measures of lung function (e.g. forced expiratory volume in
one second (FEV1))
4. Systemic markers of infection (e.g. leucocyte count, C-
reactive protein (CRP), erythrocyte sedimentation rate (ESR))
5. Adverse events (e.g. cardiac arrhythmias, GI symptoms,
hearing impairment, nephrotoxicity)
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6. Deaths
7. Emergence of resistance to antibiotics
8. Exercise capacity (e.g. Six-Minute Walk Distance
(6MWD))
9. Quality of life (e.g. St George’s Respiratory Questionnaire
(SGRQ))
10. Adverse events/side effects
Reporting one or more of the outcomes listed here is not an in-
clusion criterion for the review.
Search methods for identification of studies
Electronic searches
We will identify studies from the Cochrane Airways Group Spe-
cialised Register (CAGR), which is maintained by the Information
Specialist for the Group. The Register contains trial reports iden-
tified through systematic searches of bibliographic databases, in-
cluding theCochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE, Embase, the Cumulative Index to Nursing
and Allied Health Literature (CINAHL), the Allied and Com-
plementary Medicine Database (AMED) and PsycINFO, and by
handsearching of respiratory journals andmeeting abstracts (please
see Appendix 1 for details).We will search all records in the CAGR
using the search strategy presented in Appendix 2.
We will also conduct a search of ClinicalTrials.gov (
www.ClinicalTrials.gov) and the World Health Organization
(WHO) trials portal (www.who.int/ictrp/en/). We will search all
databases from their inception to the present, and we will impose
no restriction on language of publication.
Searching other resources
We will check the reference lists of all primary studies and review
articles for additional references and will search relevant manufac-
turers’ websites for trial information.
We will search for errata or retractions from included studies pub-
lished in full text on PubMed (www.ncbi.nlm.nih.gov/pubmed)
and will report within the review the date this was done.
Data collection and analysis
Selection of studies
Two review authors (LF and SG) will independently screen titles
and abstracts of all studies that we identify for possible inclusion
as a result of the search and will code them as ’retrieve’ (eligible or
potentially eligible/unclear) or ’do not retrieve’. We will retrieve
full-text study reports/publications, and two review authors (LF
and SG) will independently screen them to identify studies for
inclusion, and to identify ineligible studies and record reasons for
their exclusion. We will resolve disagreements through discussion,
or, if required, we will consult a third review author (SS or SJM).
We will identify and exclude duplicates and will collate multiple
reports of the same study, so that each study rather than each re-
port is the unit of interest in the review. We will record the se-
lection process in sufficient detail to complete a PRISMA (Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analy-
ses) flow diagram and ’Characteristics of excluded studies’ table
(Moher 2009).
Data extraction and management
We will use a data collection form that has been piloted on at
least one study in the review to record study characteristics and
outcome data.. One review author (RA) will extract the following
study characteristics from included studies.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
setting, withdrawals, date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, time points reported.
5. Notes: funding for trial, notable conflicts of interest of trial
authors.
Two review authors (RA and LF) will independently extract out-
come data from included studies and will note in the ’Character-
istics of included studies’ table if outcome data were not reported
in a useable way. We will resolve disagreements by consensus or by
consultation with a third review author (SS or SJM). One review
author (LF) will transfer data into the Review Manager (RevMan
2014) file. We will double-check that data have been entered cor-
rectly by comparing data presented in the systematic review with
those provided in the study reports. A second review author (RA)
will spot-check study characteristics for accuracy against the trial
report.
Assessment of risk of bias in included studies
Two review authors (LF and RA) will independently assess risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve disagreements by discussion or by consultation
with another review author (SS or SJM). We will assess risk of bias
according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
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3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will grade each potential source of bias as high, low or unclear
and will provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We
will summarise risk of bias judgements across different studies for
each of the domains listed. We will consider blinding separately
for different key outcomes when necessary (e.g. for unblinded
outcome assessment, risk of bias for all-cause mortality may be
very different from risk of bias for a patient-reported pain scale).
When information on risk of bias is related to unpublished data
or correspondence with a trialist, we will note this in the ’Risk of
bias’ table.
When considering treatment effects, we will take into account risk
of bias for studies that contributed to those outcomes.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and will report deviations from it in the ’Differences between
protocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios, and continuous
data as mean differences or standardised mean differences.We will
enter data presented as a scale with a consistent direction of effect.
We will undertakemeta-analyses only when this is meaningful (i.e.
when treatments, participants and the underlying clinical question
are similar enough for pooling to make sense).
We will narratively describe skewed data reported as medians and
interquartile ranges.
When multiple trial arms are reported in a single trial, we will
include only the relevant arms. If two comparisons (e.g. drug A vs
placebo and drug B vs placebo) are combined in the same meta-
analysis, wewill halve the control group to avoid double-counting.
Unit of analysis issues
In all included studies, the unit of analysis will be the participant.
In terms of exacerbation rates and admission rates, we plan to focus
on the number of events experienced by the participant during the
trial and to analyse the results using rate ratios if possible.
Dealing with missing data
We will contact investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data
when possible (e.g. when a study is identified as abstract only).
When this is not possible, and the missing data are thought to
introduce serious bias, we will perform a sensitivity analysis to ex-
plore the impact of including such studies in the overall assessment
of results.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
studies in each analysis. If we identify substantial heterogeneity,
we will report this and will explore possible causes by performing
prespecified subgroup analyses.
Assessment of reporting biases
If we are able to pool more than 10 studies, we will create and
examine a funnel plot to explore possible small study and publi-
cation biases.
Data synthesis
We will use a random-effects model and will perform a sensitivity
analysis using a fixed-effect model.
’Summary of findings’ table
We will create a ’Summary of findings’ table using the following
primary and secondary outcomes: exacerbations, hospitalisations,
serious adverse events, response rates, deaths and quality of life.We
will use the five GRADE considerations (study limitations, consis-
tency of effect, imprecision, indirectness and publication bias) to
assess the quality of a body of evidence as it relates to studies that
contributed data to the meta-analyses for prespecified outcomes.
We will adhere to methods and recommendations described in
Section 8.5 and Chapter 12 of the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011) and will use GRADE-
pro software (GRADEpro GDT). We will justify all decisions to
downgrade or upgrade the quality of studies by using footnotes,
and we will make comments to aid the reader’s understanding of
the review when necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
1. Duration: short (< 4 weeks) and longer (≥ 4 weeks).
2. Type of antibiotic: aminoglycosides, beta-lactams,
chloramphenicol, fluoroquinolones, macrolides, tetracyclines.
3. Children versus adults.
4. Pseudomonas colonisation versus no P seudomonas
colonisation.
We will use the following outcomes in subgroup analyses.
1. Exacerbations.
2. Hospitalisations.
3. Serious adverse events.
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We will use the formal test for subgroup interactions provided in
Review Manager (RevMan 2014).
Sensitivity analysis
We plan to evaluate the impact of methodological quality by using
the following domains to remove studies at high or unclear risk of
bias: random sequence generation and allocation concealment.
A C K N OW L E D G E M E N T S
We would like to thank Edge Hill University for supporting this
study. We would also like to thank the Cochrane Airways Group
for its support.
The Background and Methods sections of this protocol are based
on a standard template used by the Cochrane Airways Group.
RebeccaNormansell was the Editor for this review and commented
critically on the review.
This project was supported by the National Institute for Health
Research (NIHR) via Cochrane Infrastructure funding to the
Cochrane Airways Group. The views and opinions expressed
therein are those of the review authors and do not necessarily re-
flect those of the Systematic Reviews Programme, NIHR, NHS
or the Department of Health.
R E F E R E N C E S
Additional references
Chalmers 2012
Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan
JR, Hill AT. Short- and long-term antibiotic treatment
reduces airway and systemic inflammation in non-cystic
fibrosis bronchiectasis. American Journal of Respiratory and
Critical Care Medicine 2012;186(7):657–65.
Chalmers 2014
Chalmers JD, Goeminne P, Aliberti S, Melissa J. McDonnell
MJ, Lonni S, et al. The bronchiectasis severity index: an
international derivation and validation study. American
Journal of Respiratory and Critical Care Medicine 2014;189
(5):576–85.
Chang 2002
Chang AB, Grimwood K, Mulholland EK, Torzillo PJ.
Bronchiectasis in indigenous children in remote Australian
communities. The Medical Journal of Australia 2002;177
(4):200–4. [PUBMED: 12175325]
Chang 2010
Chang AB, Bell SC, Byrnes CA, Grimwood K, Holmes
P, King PT, et al. Chronic suppurative lung disease and
bronchiectasis in children and adults in Australia and New
Zealand. Medical Journal of Australia 2010;193(6):356–65.
Cole 1986
Cole PJ. Inflammation: a two-edged sword - the model
of bronchiectasis. European Journal of Respiratory Diseases.
Supplement 1986;147:6–15.
Cole 1997
Cole P. The damaging role of bacteria in chronic lung
infection. Journal of Antimicrobial Chemotherapy 1997;40
(Suppl A):5–10.
European Lung White Book 2013
Gibson GJ, Loddenkemper R, Sibille Y, Lundbäck B, editor
(s). European Lung White Book: Respiratory Health
and Disease in Europe. European Respiratory Society.
www.erswhitebook.org/, 2013.
Evans 1996
Evans SA, Turner SM, Bosch BJ, Hardy CC, Woodhead
MA. Lung function in bronchiectasis: the influence of P
seudomonas aeruginosa. European Respiratory Journal 1996;9
(8):1601–4.
Evans 2003
Evans DJ, Greenstone M. Long-term antibiotics in the
management of non-CF bronchiectasis - do they improve
outcome?. Respiratory Medicine 2003;97(7):851–8.
Foweraker 2011
Foweraker JWD. Microbiology of non-CF bronchiectasis.
European Respiratory Society Monograph 2011;52:68–96.
GRADEpro GDT [Computer program]
GRADE Working Group, McMaster University.
GRADEpro GDT. Version accessed 15 July 2016.
Hamilton (ON): GRADE Working Group, McMaster
University, 2014.
Habesoglu 2011
Habesoglu MA, Ugurlu AO, Eyuboglu FO. Clinical,
radiologic, and functional evaluation of 304 patients with
bronchiectasis. Annals of Thoracic Medicine 2011;6(3):
131–6.
Haworth 2014
Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF,
Bilton D. Inhaled colistin in patients with bronchiectasis
and chronic Pseudomonas aeruginosa infection. American
Journal of Respiratory and Critical Care Medicine 2014;189:
975-82.
Higgins 2011
Higgins JPT, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1 [updated
March 2011]. The Cochrane Collaboration, 2011.
www.cochrane-handbook.org.
6Dual antibiotics for non-cystic fibrosis bronchiectasis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kapur 2012
Kapur N, Grimwood K, Masters IB, Morris PS, Chang
AB. Lower airway microbiology and cellularity in children
with newly diagnosed non-CF bronchiectasis. Pediatric
Pulmonology 2012;47:300-7.
Kapur 2012a
Kapur N, Masters IB, Newcombe P, Chang AB. The burden
of disease in pediatric non-cystic fibrosis bronchiectasis.
Chest 2012;141(4):1018–24. [PUBMED: 21885727]
Lavery 2005
Lavery K, Bradley JM, Elborn JS. Bronchiectasis: challenges
in diagnosis and management. International Journal of
Respiratory Care 2005;1:92–8.
Lefebvre 2011
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching
for studies. In: Higgins JPT, Green S editor(s). Cochrane
Handbook for Systematic Reviews of Interventions Version
5.1.0 [updated March 2011]. The Cochrane Collaboration,
2011. www.cochrane–handbook.org.
Martinez Garcia 2007
Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera
M, Roman-Sanchez P, Soriano J. Factors associated with
lung function decline in adult patients with stable non-
cystic fibrosis bronchiectasis. Chest 2007;132(5):1565–72.
Martinez Garcia 2014
Martinez-Garcia MA, De Gracia J, Relat MV, Giron RM,
Carro LM, De La Rosa Carrillo D, et al. Multidimensional
approach to non-cystic fibrosis bronchiectasis: the FACED
score. European Respiratory Journal 2014;43:1357–67.
McShane 2013
McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic
fibrosis bronchiectasis. American Journal of Respiratory and
Critical Care Medicine 2013;188:647-56.
Moher 2009
Moher D, Liberati A, Tetzlaff J, Altman D. Preferred
reporting items for systematic reviews and meta-analyses:
the PRISMA statement. PLoS Medicine 2009;6(7):
e1000097. [DOI: 10.1371/journal.pmed.1000097]
Pasteur 2010
Pasteur MC, Bilton D, Hill AT. British Thoracic Society
Bronchiectasis Non-CF Guideline Group. British Thoracic
Society guideline for non CF bronchiectasis. Thorax 2010;
65:i1-i58.
Quint 2016
Quint JK, Millett ER, Joshi M, Navaratnam V, Thomas SL,
Hurst JR, et al. Changes in the incidence, prevalence and
mortality of bronchiectasis in the UK from 2004 to 2013: a
population-based cohort study. European Respiratory Journal
2016;47(1):186–93.
RevMan 2014 [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). Version 5.3. Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Ringshausen 2015
Ringshausen FC, de Roux A, Diel R, Hohmann D, Welte
T, Rademacher J. Bronchiectasis in Germany: a population-
based estimation of disease prevalence. The European
Respiratory Journal 2015; Vol. 46, issue 6:1805–7.
[PUBMED: 26293498]
Roberts 2010
Roberts HJ, Hubbard R. Trends in bronchiectasis mortality
in England and Wales. Respiratory Medicine 2010;104:
981–5.
Rubin 2014
Rubin BK, Williams RW. Aerosolized antibiotics for non-
cystic fibrosis bronchiectasis. Respiration 2014;88:177-84.
Seitz 2010
Seitz AE, Olivier KN, Steiner CA, Montes de Oca
R, Holland SM, Prevots DR. Trends and burden of
bronchiectasis-associated hospitalizations in the United
States, 1993-2006. Chest 2010;138(4):944–9.
Seitz 2012
Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots
DR. Trends in bronchiectasis among Medicare beneficiaries
in the United States, 2000-2007. Chest 2012;142(2):432–9.
Twiss 2005
Twiss J, Metcalfe R, Edwards E, Byrnes C. New Zealand
national incidence of bronchiectasis “too high” for a
developed country. Archives of Disease in Childhood 2005;
90(7):737–40. [PUBMED: 15871981]
Valery 2012
Valery P, Morris P, Grimwood K, Torzillo P, Byrnes C,
Masters IB, et al. Azithromycin for Indigenous children
with bronchiectasis: study protocol for a multi-centre
randomized controlled trial. BMC Paediatrics 2012;12:122.
Weycker 2005
Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and
economic burden of bronchiectasis. Clinical Pulmonary
Medicine 2005;12:205–9.
Wilson 1997
Wilson CB, Jones PW, O’Leary CJ, Hansell DM, Cole PJ,
Wilson R. Effect of sputum bacteriology on the quality of
life of patients with bronchiectasis. European Respiratory
Journal 1997;10:1754–60.
Wu 2014
Wu Q, Shen W, Cheng H, Zhou X. Long-term macrolides
for non-cystic fibrosis bronchiectasis: a systematic review
and meta-analysis. Respirology 2014;19(3):321-9.
∗ Indicates the major publication for the study
7Dual antibiotics for non-cystic fibrosis bronchiectasis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
CENTRAL (the Cochrane Library) Monthly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
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Bronchiectasis search
1. exp Bronchiectasis/
2. bronchiect$.mp.
3. bronchoect$.mp.
4. kartagener$.mp.
5. (ciliary adj3 dyskinesia).mp.
6. (bronchial$ adj3 dilat$).mp.
7. or/1-6
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter (Lefebvre 2011) were adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 BRONCH:MISC1
#2 MeSH DESCRIPTOR Bronchiectasis Explode All
#3 bronchiect*
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Anti-Bacterial Agents Explode 1
#6 antibiotic* or anti-biotic*
#7 anti-bacteri* or antibacteri*
#8 *cillin
#9 *mycin or micin*
#10 *oxacin
#11 *tetracycline
#12 macrolide*
#13 quinolone*
#14 trimethoprim
#15 ceph*
#16 sulpha*
#17 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 #4 and #17
[In search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case, bronchiectasis]
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